Peter Attia MDPros and cons of GLP-1 weight loss drugs and metformin as a geroprotective agent [AMA 45 sneak peek]
At a glance
WHAT IT’S REALLY ABOUT
Peter Attia Explains GLP-1 Drugs, Semaglutide, Tirzepatide, and Metformin's Geroprotective Role
- Peter Attia says semaglutide and its relatives are now the most talked-about drugs, a topic his team studied as early as spring 2020 and he now holds a much stronger view on.
- He explains that GLP-1 and GIP are gut hormones that raise insulin release and suppress glucagon, which lowers blood glucose, and that the drugs began as type 2 diabetes treatments before their weight-loss effects were recognized.
- He distinguishes semaglutide, a pure GLP-1 agonist sold as Ozempic and Wegovy, from tirzepatide, a GIP and GLP-1 co-agonist sold as Mounjaro, covering their dosing, approvals, and weekly injection format.
- He defines 'geroprotective' as describing drugs that act broadly across hallmarks of aging, citing rapamycin, SGLT2 inhibitors, and possibly metformin, and says metformin will be discussed in that light rather than for diabetes.
- He voices concern that many people asking about these drugs for weight loss are not overweight and want to lose about 10 pounds for a vacation, while others have a genuine need.
IDEAS WORTH REMEMBERING
5 ideasThese drugs began as diabetes treatments
GLP-1 and GIP agonists were developed for type 2 diabetes, and weight loss was observed in people taking them alongside improved glycemic control.
The reason for weight loss is not fully understood
Attia says there is agreement it is a central effect that reduces appetite, but it is not clear exactly why GLP-1 acts centrally to do so.
Ozempic and Wegovy are the same drug
Both are semaglutide, differing basically in branding and dosing, with Wegovy dosed up to 2.4 mg weekly and recently approved for kids 12 and up.
Tirzepatide works differently from semaglutide
Tirzepatide is a co-agonist with roughly a quarter of native GLP-1's potency by one affinity measure but GIP activity virtually identical to native GIP.
Lower potency was a deliberate design choice
Semaglutide was made slightly less potent than native GLP-1 to give it a much longer half-life, allowing weekly rather than multiple daily injections.
WORDS WORTH SAVING
5 quotesThere, there cannot be a drug that is getting more attention right now than semaglutide and, and its ilk, right?
— Peter Attia
Perhaps more disturbing to me is the people who are reaching out to me who are frankly not overweight remotely, um, but are saying, like, "I really want to lose 10 pounds to look good on my vacation, and I should be taking this, right?"
— Peter Attia
They're probably doing a lot of things that overall improve lifespan and healthspan beyond just kind of whack-a-mole-ing one disease at a time.
— Peter Attia
So when you take these hormones, your appetite goes down, you eat less, you lose weight. It's relatively straightforward.
— Peter Attia
This, this, this, this, this, uh, book is, uh, is like a cat that died eight times and somehow managed to, to, to, to eke out survival before the ninth and final death.
— Peter Attia
High quality AI-generated summary created from speaker-labeled transcript.
